An old molecule to fight SARS-CoV-2
Source : https://nouvelles.umontreal.ca/en/article/2022/02/10/an-old-molecule-to-fight-sars-cov-2/
In the spring of 2020, Université de Montréal biochemistry professor Christian Baron had an idea: why not evaluate the inhibition capacity of a commercially available molecule called VE607 on the...
In their study, done in collaboration with colleagues at the University of Ottawa and four U.S. universities, the two co-authors and their lab teams also found that VE607 stabilizes the receptor-binding domain (RBD) in its “up” conformation.
Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses
Source : https://pubs.acs.org/doi/10.1021/jacs.1c08402
Drugs targeting SARS-CoV-2 could have saved millions of lives during the COVID-19 pandemic, and it is now crucial to develop inhibitors of coronavirus replication in preparation for future outbreaks. We...
Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
Source : https://ard.bmj.com/content/early/2022/02/07/annrheumdis-2021-221735
Objectives To evaluate the distinct impact of disease modifying antirheumatic drugs (DMARD) combination and monotherapy in immune response to an inactivated SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA). Methods...
Conclusions: Patients with RA under DMARD have a moderate immunogenicity to CoronaVac. We identified that nearly all DMARD combinations have a deleterious effect in immunogenicity, whereas a more restricted number of drugs (methotrexate/tofacitinib/abatacept/tocilizumab) also hampered this response as monotherapy. These findings reinforce the...
Conclusion: TMPRSS2 rs12329760 is a common variant associated with a significantly decreased risk of severe COVID-19. Further studies are needed to assess the expression of TMPRSS2 across different age groups. Moreover, our results identify TMPRSS2 as a promising drug target, with a potential role for camostat mesilate, a drug approved for the...
Highlights
- Exercise increases antibody response to COVID-19 and Influenza vaccines.
- Exercise performed after COVID-19 vaccine does not increase side effects.
- Interferon-α may contribute to exercise-induced enhancement of vaccine response.